In interviewed adults with osteosarcoma, surveillance identified no patients with prior teriparatide treatment.
In plain wordsAmong interviewed adults with bone cancer, none reported prior teriparatide treatment.
- Peptide
- Teriparatide (PTH 1-34)
- Outcome
- Not applicablePrior teriparatide exposure among osteosarcoma cases
- Study
n = 549
- Outcome group
- Adverse events · Cancer
Source sentences
After 7 years of the study, there were no osteosarcoma patients who had a prior history of teriparatide treatment.
3 context sentences(design, population, supporting numbers)
Incident cases of primary osteosarcoma diagnosed in adults (aged ≥40 years) on or after January 1, 2003, are identified through population-based state, regional, and comprehensive cancer center registries in the US.
Information on possible prior treatment with teriparatide, on demographics, and on risk factors is ascertained by patient or proxy telephone interview after patient consent.
Between June 2004 and September 30, 2011, 1448 cases (diagnosed 2003 to 2009) were identified by participating cancer registries (estimated to be 62% of all adult cases in the US for that time period); 549 patients or proxies were interviewed.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).